Corresponding Author: Natasha S. Wylie, DNP, APRN, Division of Hematology and Medical Oncology, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224 (wylie.natasha@mayo.edu).
Published Online: October 28, 2021. doi:10.1001/jamaoncol.2021.5578
Conflict of Interest Disclosures: Dr Starr reported receiving honoraria for consulting from Natera, Pfizer, TerSera Therapeutics, Ipsen, and Advanced Accelerator Applications outside the submitted work. No other disclosures were reported.
Additional Contributions: We thank the patient for granting permission to publish this information.
4.Pemazyre (pemigatinib). Package insert. Incyte Corporation; 2020.
7.Lacouture
ME , Sibaud
V , Anadkat
MJ ,
et al. Dermatologic adverse events associated with selective fibroblast growth factor receptor inhibitors: overview, prevention, and management guidelines.
Oncologist. 2021;26(2):e316-e326. doi:
10.1002/onco.13552
PubMedGoogle ScholarCrossref 8.Arudra
K , Patel
R , Tetzlaff
MT ,
et al. Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor.
J Cutan Pathol. 2018;45(10):786-790. doi:
10.1111/cup.13319
PubMedGoogle ScholarCrossref